Alumni Ventures invests in Evvy
Funding Provisional 88% confidence first seen
Women’s health AI startup Evvy (Allora Health Inc.) reported closing a $40 million Series B funding round, with Alumni Ventures participating as one of the new investors. The round was led by Catalio Capital Management and also included investors such as the U.S. Fertility Innovation Fund, Rethink Impact, and Muse Capital. The reported use of proceeds is to scale and validate AI-enabled diagnostic and care models, starting with fertility-focused care, which matters for expanding precision diagnostics and treatment planning in women’s health.
The deal
Evvy $40M Series B · announced 15 Sep 2026
Investors Alumni Ventures Catalio Capital Management
Deal terms as reported in the coverage below.
Decision brief
- What changed
- Evvy, a women’s health AI startup, reported closing a $40 million Series B round, with Alumni Ventures participating alongside lead investor Catalio Capital Management and other investors. The company said it will use the funding to scale and validate AI-enabled diagnostic and care models, beginning with fertility-focused care.
- Why it matters
- This financing gives Evvy resources to expand an AI-based diagnostics and care platform in a clinically important and historically underserved segment of healthcare. For decision-makers, the event signals continued investor support for precision-diagnostics businesses that pair AI with care delivery, especially where companies can point to reported outcome improvements and a near-term commercialization focus such as fertility care.
- Evidence
- The provided coverage comes from a single SiliconANGLE article reporting the $40 million Series B, the investor group, and Evvy’s stated use of proceeds. The same article attributes performance claims such as diagnosing more than 90% of symptomatic patients and reducing recurrence by 50% to the company’s own reporting, so independent corroboration is limited in the supplied coverage.
- What remains uncertain
- Open questions include how much Alumni Ventures invested, the valuation and terms of the round, and whether Evvy’s reported clinical performance has been independently validated at scale. It is also not confirmed in the provided coverage how quickly fertility-focused offerings will launch or what regulatory, reimbursement, and provider-adoption hurdles could affect execution.
- Monitor next
- Watch for independent clinical validation or commercial rollout details for Evvy’s fertility-focused AI care models, especially partnerships, published outcomes, or reimbursement-related announcements.
Analytical support, not advice — assumptions and open questions stated above.